Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Caroline M. Robb, Jacob I. Contreras, Smit Kour, et al.
Chemical Communications (2017) Vol. 53, Iss. 54, pp. 7577-7580
Open Access | Times Cited: 189

Showing 1-25 of 189 citing articles:

Kinase inhibitors: the road ahead
Fleur M. Ferguson, Nathanael S. Gray
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 5, pp. 353-377
Closed Access | Times Cited: 892
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Mariell Pettersson, Craig M. Crews
Drug Discovery Today Technologies (2019) Vol. 31, pp. 15-27
Open Access | Times Cited: 598
Trends in kinase drug discovery: targets, indications and inhibitor design
Misty M. Attwood, Doriano Fabbro, Aleksandr V. Sokolov, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 839-861
Closed Access | Times Cited: 574
PROTACs: great opportunities for academia and industry
Xiuyun Sun, Hongying Gao, Yiqing Yang, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 513
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva, Craig M. Crews
Current Opinion in Chemical Biology (2019) Vol. 50, pp. 111-119
Open Access | Times Cited: 478
Bromodomains: a new target class for drug development
Andrea G. Cochran, Andrew R. Conery, Robert J. Sims
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 8, pp. 609-628
Closed Access | Times Cited: 375
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li, Yongcheng Song
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 328
Proteolysis targeting chimeras (PROTACs) in ‘beyond rule-of-five’ chemical space: Recent progress and future challenges
Scott D. Edmondson, Bin Yang, Charlene Fallan
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 13, pp. 1555-1564
Closed Access | Times Cited: 316
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Sainan An, Liwu Fu
EBioMedicine (2018) Vol. 36, pp. 553-562
Open Access | Times Cited: 303
Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
Vittoria Zoppi, Scott J. Hughes, Chiara Maniaci, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 2, pp. 699-726
Open Access | Times Cited: 292
Cell cycle on the crossroad of tumorigenesis and cancer therapy
Jing Liu, Yunhua Peng, Wenyi Wei
Trends in Cell Biology (2021) Vol. 32, Iss. 1, pp. 30-44
Open Access | Times Cited: 261
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
Yangbing Li, Jiuling Yang, Angelo Aguilar, et al.
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 2, pp. 448-466
Open Access | Times Cited: 254
Degradation of proteins by PROTACs and other strategies
Yang Wang, Xueyang Jiang, Feng Feng, et al.
Acta Pharmaceutica Sinica B (2019) Vol. 10, Iss. 2, pp. 207-238
Open Access | Times Cited: 254
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu, Biao Hu, Mingliang Wang, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 3, pp. 1420-1442
Closed Access | Times Cited: 231
The PROTAC technology in drug development
Yutian Zou, Danhui Ma, Yinyin Wang
Cell Biochemistry and Function (2019) Vol. 37, Iss. 1, pp. 21-30
Open Access | Times Cited: 226
Light-induced control of protein destruction by opto-PROTAC
Jing Liu, He Chen, Leina Ma, et al.
Science Advances (2020) Vol. 6, Iss. 8
Open Access | Times Cited: 222
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Chengwei Zhang, Xiaoran Han, Xiaobao Yang, et al.
European Journal of Medicinal Chemistry (2018) Vol. 151, pp. 304-314
Open Access | Times Cited: 192
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Sajid Khan, Yonghan He, Xuan Zhang, et al.
Oncogene (2020) Vol. 39, Iss. 26, pp. 4909-4924
Open Access | Times Cited: 189
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Shanique Alabi, Craig M. Crews
Journal of Biological Chemistry (2021) Vol. 296, pp. 100647-100647
Open Access | Times Cited: 189
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 188
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Concepción Sánchez‐Martínez, Marı́a José Lallena, Sonia Gutiérrez Sanfeliciano, et al.
Bioorganic & Medicinal Chemistry Letters (2019) Vol. 29, Iss. 20, pp. 126637-126637
Closed Access | Times Cited: 178
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 172
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Rati Verma, Dane Mohl, Raymond J. Deshaies
Molecular Cell (2020) Vol. 77, Iss. 3, pp. 446-460
Open Access | Times Cited: 171
Chemistries of bifunctional PROTAC degraders
Chao-Guo Cao, Ming He, Liguo Wang, et al.
Chemical Society Reviews (2022) Vol. 51, Iss. 16, pp. 7066-7114
Closed Access | Times Cited: 170
E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points
Aleša Bricelj, Christian Steinebach, Robert D. Kuchta, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 158
Page 1 - Next Page

Scroll to top